Insulet Co. (NASDAQ:PODD) has received a consensus recommendation of “Buy” from the eighteen analysts that are presently covering the company, MarketBeat reports. Nine investment analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1-year target price among brokers that have covered the stock in the last year is $152.93.

A number of equities research analysts recently commented on the company. Guggenheim downgraded Insulet from a “buy” rating to a “neutral” rating in a research report on Thursday, October 3rd. They noted that the move was a valuation call. Stifel Nicolaus assumed coverage on Insulet in a report on Tuesday, October 22nd. They set a “hold” rating and a $163.00 price target for the company. BidaskClub upgraded Insulet from a “buy” rating to a “strong-buy” rating in a report on Saturday. Canaccord Genuity downgraded Insulet from a “buy” rating to a “hold” rating and lifted their price objective for the stock from $135.00 to $145.00 in a research note on Friday, October 18th. Finally, UBS Group cut Insulet from a “buy” rating to a “neutral” rating and upped their price objective for the stock from $155.00 to $160.00 in a report on Friday, October 4th. They noted that the move was a valuation call.

In other Insulet news, Director John A. Fallon sold 14,525 shares of the company’s stock in a transaction that occurred on Monday, November 18th. The stock was sold at an average price of $181.21, for a total transaction of $2,632,075.25. Also, CEO Shacey Petrovic sold 689 shares of the firm’s stock in a transaction that occurred on Friday, November 1st. The shares were sold at an average price of $145.69, for a total value of $100,380.41. Following the completion of the sale, the chief executive officer now directly owns 94,510 shares of the company’s stock, valued at $13,769,161.90. The disclosure for this sale can be found here. 3.50% of the stock is currently owned by company insiders.

Institutional investors have recently made changes to their positions in the company. Advisors Preferred LLC purchased a new position in shares of Insulet during the 2nd quarter worth about $38,000. Harvest Fund Management Co. Ltd purchased a new stake in Insulet in the 2nd quarter worth about $43,000. Mitsubishi UFJ Securities Holdings Co. Ltd. purchased a new stake in Insulet in the 2nd quarter worth about $97,000. Steward Partners Investment Advisory LLC bought a new stake in Insulet in the second quarter worth about $119,000. Finally, Cerebellum GP LLC bought a new stake in Insulet in the third quarter worth about $122,000.

NASDAQ PODD traded up $2.14 on Tuesday, reaching $184.04. The company had a trading volume of 531,100 shares, compared to its average volume of 769,879. The stock has a market capitalization of $11.48 billion, a PE ratio of 3,680.80 and a beta of 1.04. Insulet has a 12 month low of $70.80 and a 12 month high of $187.25. The company has a quick ratio of 6.21, a current ratio of 7.01 and a debt-to-equity ratio of 6.55. The firm’s 50 day moving average price is $165.06 and its 200 day moving average price is $141.22.

Insulet (NASDAQ:PODD) last released its quarterly earnings data on Tuesday, November 5th. The medical instruments supplier reported $0.01 EPS for the quarter, missing the consensus estimate of $0.03 by ($0.02). The company had revenue of $192.12 million for the quarter, compared to the consensus estimate of $179.50 million. Insulet had a net margin of 2.38% and a return on equity of 10.34%. The firm’s revenue for the quarter was up 27.2% on a year-over-year basis. During the same period last year, the company earned $0.03 EPS. On average, research analysts expect that Insulet will post 0.25 EPS for the current year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company offers Omnipod System, which consists of self-adhesive disposable tubeless Omnipod device (the pod) that delivers insulin into the body; and Personal Diabetes Manager, a handheld wireless device, which programs the Pod.

Further Reading: Buy Rating

Analyst Recommendations for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.